Trump says the main pharmaceutical rates come soon

A version of this article appeared for the first time in the CNBC Healthy Returns newsletter, which brings the latest news of health care directly in your reception box. Subscribe here To receive future editions.

President Donald Trump has doubled the plans to soon impose “major” prices on pharmaceutical products imported into the United States

This comes after the manufacturers of drugs pushed a temporary sigh of relief last week, when Trump exempted the sector from his large round of so-called reciprocal rates.

“We will quickly announce a major price on pharmaceutical products,” he said on Tuesday during a dinner of the National Committee of the Republican Congress, according to several media. “And when they hear this, they will leave China. They will leave other places because they have to sell – most of their product is sold here and they will open their plants everywhere.”

In the United States, the manufacture of drugs has decreased considerably in recent decades. The production of most so-called ingredients active in drugs has moved to China and other countries, largely due to the drop in labor costs and other parts of the process, according to the Food and Drug Administration.

We do not know what these prices will look like. But Trump said on the Air Force One last week that the “pharmaceutical” prices would arrive “at a level that you had not really seen before”, according to several reports.

Already, the pharmaceutical industry pushes, just a few weeks after some companies have announced US manufacturing investments to build goodwill with Trump.

Eli Lilly CEO David Ricks warned on Friday that Trump’s decision to impose large prices could ultimately affect the research and development of drugs.

“We cannot violate these agreements, so we have to eat the cost of prices and compromise within our own businesses,” Ricks in BBC told an interview. “As a rule, it will be in reduction of staff or research and development, and I predict that R&D will come first. It is a disappointing result.”

Eli Lilly has led industry to strengthen its American production capacities, to make $ 50 billion to build and improve new factories since 2020. These facilities have been essential to manufacture the weight loss and diabetes drugs.

But Eli Lilly also depends mainly on foreign manufacturing, especially in Ireland, where it employs more than 3,000 people and built a new installation of $ 800 million.

Specific pharmaceutical prices would probably increase the prices of American drugs, because even if companies moved to produce these drugs at the national level, it would take more than to produce drugs abroad, said Leerink Partners analyst David Risinger, in a note last month.

It is difficult to predict the potential impact of prices on pharmaceutical companies because they have large and complex manufacturing networks with several stages, sometimes in different countries, said TD Cowen Scala TD analyst in a note last week.

But Scala said that Eli Lilly, Bristol Myers Squibb and Abbvie seem better positioned than the others to resist prices because they have more important manufacturing factories in the United States than international.

The majority of their sites responsible for the production of active ingredients in drugs are also in the United States, he added.

Meanwhile, Novartis and Roche “look more” because they have few American plants and a higher share of active ingredient sites that are international, said Scala.

Do not hesitate to send advice, suggestions, history ideas and data to Annikakim.constantino@nbcuni.com.

Although January can feel 10 years ago (at least it is the fact to this tired journalist), we are only a quarter of 2025. Here is what happened with the financing of digital health during the period, according to a new report of rock health.

In the first quarter, $ 3 billion was invested in digital health in 122 offers, Rock Health said. Funding increased slightly, but the number of transactions decreased, compared to the $ 2.7 billion invested in 133 transactions during the same period last year.

The sector won $ 1.8 billion in funding in 118 transactions in the fourth quarter of last year.

Small startups in the start -up phase dominated the space in the first quarter of 2025, while Seed, Series A and the B series represent 83% of the labeled offers, said Rock Health.

The company calls towers without public title (such as series A, for example) “rounds not labeled”. Startups often raise unmarked rounds to avoid taking evaluation haircuts and going through difficult markets, although they often do not allow these difficult conversations forever.

Only five companies noted round of labeled or later in the first quarter, and three of these towers exceeded more than $ 100 million. The Innovaccer health care data company announced an increase of $ 275 million in January, the Automation Company of AI Qvetus announced a round of $ 105 million in January and the AI ​​Abridge Scribdage company announced an increase of $ 250 million in February.

These transactions helped to draw the size of the median round from the subsequent stadium to $ 105 million, almost double the median size of $ 55 million for this cohort from 2024.

While the first quarter of the year was free from major disruptions to the financing of the company in digital health, the second quarter could arouse more challenges.

Public markets have taken a tour of President Donald Trump announced last week an aggressive and large -scale “reciprocal” prices policy, plunging the United States – and its business partners – in uncertain territory. Last week, the Nasdaq Composite recorded its worst week since the start of the cocovated pandemic and entered a lower market.

The prices entered into force on Wednesday, although investors have no clarity yet: Trump reported that he could negotiate with business partners on the reduction of their potentially prices. The World Trade Conflict changes minute, which could make certain venture capital investors hesitating to reduce large short-term checks.

CNBC covers all the latest developments, and you can follow our cover live here.

Do not hesitate to send advice, suggestions, history ideas and data to Ashley to Ashley.capoot@nbcuni.com.